viewTenet Healthcare

Tenet Healthcare Corp, Fitbit, Palo Alto Networks and more - AFTER HOURS

Proactive takes a look at what was moving the needle after the bell in New York

Fitbit and NutriSystem Inc were stocks in focus after the bell

Wall Street stomped to a higher close on Monday, and after the bell, Tenet Healthcare Corp (NYSE:THC) followed the trend, jumping almost 8% to US$20.57.

The Dallas -based healthcare services firm's earnings and revenue beat Wall Street expectations.

Meanwhile, fourth quarter sales were higher than expected and guidance for the upcoming year was strong.

Elsewhere, Fitbit Inc (NYSE:FIT) shares went the other way, sagging over 15% to US$4.68 after the New York bell.

It came after the much talked about wearable tech firm reported losses per share of 2 cents and revenues that missed expectations by US$18mln.

The firm's fourth-quarter results also missed estimates due to an about 17% fall  in the sale of its fitness trackers in the holiday quarter.

The firm has faced competition from tech behemoth Apple (NASDAQ:AAPL), which has now become a stronger contender in the sector.

Meanwhile,  in a similar vein, shares of NutriSystem Inc (NASDAQ:NTRI) the weight loss group, tanked over 27% to US$ 28.95 in New York after it announced earnings per share and revenues that beat analyst expectations, but weak guidance sent the stock plummeting.

Elsewhere, in extended hours, Akorn Inc (NASDAQ:AKRX) shares tanked over 35% to US$19.50 as the Illinois based generic pharma group is under investigation by acquirer Fresenius regarding alleged breaches of FDA data integrity requirements relating to product development.

Palo Alto Networks Inc (NYSE:PANW), the network security firm, added 6.3% after the bell to US$ 179.98 after it posted growth in revenue as well as EPS (earnings per share) and revenues that surpassed expectations.

Quick facts: Tenet Healthcare

Price: 33.4 USD

Market: NYSE
Market Cap: $3.47 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Faron Pharma CEO confident as he looks ahead to new Traumakine study

Faron Pharmaceuticals Oy (LON:FARN) (FIRSTNORTH:FARON) CEO Dr Markku Jalkanen caught up with Proactive London's Andrew Scott soon after announcing they've amended the protocol for a second phase III study of its drug for acute respiratory distress syndrome (ARDS). The tweak's in response to...

15 hours, 14 minutes ago

2 min read